Rubedo Life Sciences, Inc Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Sunnyvale CA US

Primary Industry

Biotechnology

About

Founded in 2018 and based in California, US, Rubedo Life Sciences, Inc. operates as a biopharmaceutical company. The company was founded by its CEO, Marco Quarta, Mark Gallop, and Julian Klein. In April 2024, Rubedo Life Sciences, Inc. raised USD 40 million in Series A funding co-led by Ahren Innovation Capital, Khosla Ventures, Hevolution Foundation, R42, and Modi Ventures. The series A funding values Rubedo Life Sciences, Inc. at USD 89.71 million post-money. Rubedo Life Sciences develops drugs, mainly small molecules, to target and eliminate senescent cells. The firm's lead drug candidate, RLS-1496, is a topical medication designed to remove senescent cells from skin lesions and used for the treatment of dermatological conditions. The company plans to use the funds raised in April 2024 to develop drugs for inflammatory and fibrotic diseases.

Current Investors

Khosla Ventures, Shanda Capital, The Longevity Fund

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals

Website

www.rubedolife.com

Verticals

Manufacturing

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.